There is a highly sophisticated way to treat some breast and ovarian cancers—a class of drugs called PARP inhibitors, designed to exploit the very defects that make tumors with certain mutations especially deadly. Yet this ...
Jul 18, 2018
0
55
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests ...
Jul 16, 2018
0
43
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors.
May 10, 2018
0
194
A study at The University of Texas MD Anderson Cancer Center has shown promise for effective treatment of therapy-resistant cancers caused by a mutation of the RAS gene found in many cancers. The pre-clinical study combined ...
Jun 2, 2017
0
163
The Food and Drug Administration's recent approval of the drug olaparib for ovarian cancer patients with inherited mutations in the genes BRCA1 or BRCA2 came as welcome news to the thousands of women now eligible to receive ...
Feb 16, 2015
0
59
A new study published in Science May 11 is shedding light on the molecular details of PARP-1, a DNA damage-detecting enzyme that when inhibited has been shown to be effective in fighting cancer and other diseases.
May 10, 2012
0
0
PARP inhibitors have improved survival of breast cancer patients with BRCA1/2 mutations, but the drugs eventually stop working and the cancer returns.
Aug 15, 2024
0
28
Researchers at The Institute of Cancer Research, London, have increased our understanding of how a cancer drug called a PARP inhibitor stops working in women with breast cancer that has spread. This research could ultimately ...
May 8, 2024
0
2
Patient prognosis and treatment response prediction are key factors in treating ovarian cancer, which is characterized by the lowest survival rate among gynecological cancers. Consequently, there is strong demand for a more ...
Apr 15, 2024
0
0
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results ...
Apr 8, 2024
0
0
